The ABO blood group has been linked to the inherent risk of pancreatic cancer.1 However, few studies have investigated its prognostic role and interaction with adjuvant chemotherapy regimens in patients with resected pancreatic cancer.2,3 Furthermore, there have been only limited data linking blood group antigen expression in pancreatic cancer cells to survival outcomes.4 This evidence concerns the gene ABO and familial pancreatic carcinoma.